Cytek Biosciences
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 23% of the universe, above its 200-day average.
- Signal has read BUY for 3 weeks.
- Recent price momentum is +28.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 5.36
- Open
- 5.32
- Day range
- 5.30 - 5.56
- Avg price
- 5.43
- Volume
- 3.88M
- Turnover
- 21.08M
- Turnover ratei
- 3.77%
- Volume ratioi
- 2.30
- Amplitudei
- 4.76%
- 52-week rangei
- 3.31 - 6.21
Valuation
- P/Ei
- -10.44
- P/E (TTM)i
- -8.62
- P/Bi
- 2.19
- EPSi
- -0.52
- Book value / shi
- 2.48
- Net profit
- -67.59M
- Net assets
- 321.97M
Share structure
- Market cap
- 705.81M
- Float capi
- 558.97M
- Shares out
- 129.98M
- Float sharesi
- 102.94M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-07-23
12.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.89M net over the window
Short interest
- Shares short
- 5.22M
- % of floati
- 4.01%
- Days to coveri
- 3.13
- As of
- 2026-09-30
Frequently asked questions
What is the current stock price of Cytek Biosciences (CTKB)?
Cytek Biosciences last traded at 5.43. The quote on this page refreshes every few seconds while US markets are open.
What is Cytek Biosciences's market cap?
About 705.81M.
What is the P/E ratio of Cytek Biosciences?
The trailing twelve-month P/E is -8.62. The Valuation tab shows it against the stock's own five-year range.
Does Cytek Biosciences pay a dividend?
Cytek Biosciences does not currently pay a regular dividend.
Is Cytek Biosciences a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 6.00, which implies 10.5% upside from the current price. This is not investment advice.
What is Cytek Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Cytek Biosciences a B (Buy). Twelve-month momentum in the top 23% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-09 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Cytek Biosciences discussion 0 comments